Recent Updates
Recently added Catalysts

SR141716

Phase 2

Healthy | Small molecule | Other |Sanofi|Last Updated: Jul 2, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment54
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00075205Rimonabant to Reduce Alcohol ConsumptionPHASE2 COMPLETED 54Dec 31, 2003Mar 15, 2007Jul 2, 20171 United States
Unlock Drug Trial Details
Study Design & Arms
PurposeTREATMENT
Interventions
NameTypeDescription
SR141716 (Rimonabant)DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range21 Years — 45 Years
SexALL
Healthy VolunteersNo
Study Sites1

* INCLUSION CRITERIA Male and female healthy participants, between 21 and 45 years of age. Weight and Body Mass Index: Males: between 60 kg and 90 kg; Body Mass Index between 18 and 28. Females: between 45 kg and 80 kg; Body Mass Index between 18 and 28. Certified as healthy by a comprehensive ...

Countries:United States
Unlock Eligibility Criteria